← Back

MicroPort Scientific Corp

MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People's Republic of China, the United States of America, Europe, Middle East and Africa, Japan, and internationally. The company's Cardiovascular Devices segment offers medical solutions for the treatment of coronary artery-related diseases; and coronary stents, related delivery systems, balloon catheters, accessories, and active devices. Its Orthopedics Devices segment provides reconstructive joints, spine and trauma products, and other professional implants and instruments. The company's Cardiac Rhythm Management Business segment offers defibrillators, cardiac resynchronization therapy devices, and pacemakers. Its Endovascular and Peripheral Vascular Devices segment provides disease solutions for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection aneurysms, and other arteriovenous related diseases. The company's Neurovascular Devices segment offers neurovascular therapeutic and access devices for cerebrovascular diseases. The company's Surgical Robot Business segment offers surgical robots comprising robot ontology, control algorithm, electrical engineering, image-based navigation, and precision imaging. Its Structural Heart Disease Business segment provides heart valve devices. It is also involved in the distribution of medical devices. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.

Price · split & dividend adjusted
News & notes moving 0853.HK
Robotics & Physical AI4

TINAVI Plans Share Issuance to Acquire Controlling Stake in Shanghai MicroPort Orthopedics; Shares Halted from the 16th

TINAVI announced that the company is planning to acquire a controlling stake in Shanghai MicroPort Orthopedics Medical Technology Co., Ltd. through a share issuance, while also intending to raise matching funds. The transaction is expected to constitute a major asset restructuring but not a restructuring listing. Trading in the company’s shares will be suspended from July 16, 2026, with the halt expected to last no more than five trading days. The target company is a controlled subsidiary of Suzhou MicroPort Orthopedics Group Co., Ltd., which is under MicroPort Scientific Corporation, and serves as the core operating entity for MicroPort’s international non-China orthopedics business. It primarily engages in knee and hip reconstruction in overseas markets such as the United States, Japan, and Europe, with products including hip prostheses, knee prostheses, and other orthopedic implants, and has a well-established overseas sales network. Its flagship product, the medial pivot knee, has over 20 years of clinical application history, with cumulative global implantations exceeding one million cases. This transaction will help TINAVI enhance its orthopedic product portfolio, build a comprehensive solution of robotics plus implants plus consumables plus services, and accelerate its international expansion.
688277.CG ▲0853.HK
Robotics & Physical AI ▲
科创板日报·43dRead more ▾
0853.HK▲

MicroPort Scientific Plans to Sell 82.29% Stake in Shanghai MicroPort Orthopedics to Tinavi

MicroPort Scientific has issued a voluntary announcement stating that its subsidiary, Suzhou MicroPort Orthopedics Group, signed a letter of intent on July 15, 2026, with Beijing Tinavi Medical Technologies, proposing to sell its 82.29% equity interest in Shanghai MicroPort Orthopedics Medical Technology. The transaction consideration will be paid through the issuance of new shares by Tinavi. This potential deal is still at a preliminary negotiation stage. Key terms such as the exact transfer ratio, number of shares to be issued, and issue price are subject to further commercial negotiations, and the transaction is conditional upon completion of due diligence, signing of formal agreements, and obtaining relevant regulatory approvals. Shanghai MicroPort Orthopedics serves as the core operating entity for MicroPort Scientific's international orthopedics business, focusing on the research and development of hip and knee joint prostheses and overseas sales. Its medial pivot knee prosthesis has a 17-year implant survival rate of 98.80%, covering markets including the United States, Japan, and Europe. The transaction aims to integrate high-end prosthesis products with intelligent surgical platform resources through strategic synergy with Tinavi, a leading domestic orthopedic surgical robot company, thereby enhancing long-term investment value. The announcement cautions that the potential transaction involves uncertainties and does not constitute a commitment that the deal will necessarily be implemented.
0853.HK ▲688277.CG ▲
南方财经网·43dRead more ▾
© 2026 MarketDXAsset